FDA Closed-Door Hemopure Meeting Violates Advisory Committee Act, Cries Wolfe
This article was originally published in The Pink Sheet Daily
Public Citizen is seeking a temporary restraining order against FDA’s Blood Products Advisory Committee closed-door review of Biopure’s oxygen therapeutic.
You may also be interested in...
The day before Biopure's July 14 review, FDA's Blood Products Advisory Committee will discuss Nabi's Nabi-HB immunoglobulin for hepatitis B.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.